+ Watch DNDNQ
on My Watchlist
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acceptance of any treatment that cannot compete on the basis of cost. In this environment their best hope is that their stock price continues to fall to a level where a larger pharm company buys them out for their patents. This may help some of the people that work for the company but it won't help the investors.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions